BTK inhibitors are considered promising candidates for MS therapy, as they can cross the blood-brain barrier (123) and, through their additional effect on the innate immune system, they may also address compartmentalized inflammation, which is of particular importance in mediating brain damage and driving disability of MS (119, 124–127). Here, BTK is linked to myeloid sarcoma.